Cargando…

Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma

INTRODUCTION: Necroptosis is a novel pattern of immunogenic cell death and has triggered an emerging wave in antitumor therapy. More evidence has suggested the potential associations between necroptosis and intra-tumoral heterogeneity. Currently, the underlying role of necroptosis remains elusive in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Bowen, Gao, Jie, Shi, Jihua, Zhang, Feng, Shi, Chengcheng, Wen, Peihao, Wang, Zhihui, Guo, Wenzhi, Zhang, Shuijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363630/
https://www.ncbi.nlm.nih.gov/pubmed/35967375
http://dx.doi.org/10.3389/fimmu.2022.970117
_version_ 1784764968705458176
author Hu, Bowen
Gao, Jie
Shi, Jihua
Zhang, Feng
Shi, Chengcheng
Wen, Peihao
Wang, Zhihui
Guo, Wenzhi
Zhang, Shuijun
author_facet Hu, Bowen
Gao, Jie
Shi, Jihua
Zhang, Feng
Shi, Chengcheng
Wen, Peihao
Wang, Zhihui
Guo, Wenzhi
Zhang, Shuijun
author_sort Hu, Bowen
collection PubMed
description INTRODUCTION: Necroptosis is a novel pattern of immunogenic cell death and has triggered an emerging wave in antitumor therapy. More evidence has suggested the potential associations between necroptosis and intra-tumoral heterogeneity. Currently, the underlying role of necroptosis remains elusive in hepatocellular carcinoma (HCC) at antitumor immunity and inter-tumoral heterogeneity. METHODS: This study enrolled a total of 728 HCC patients and 139 immunotherapy patients from eight public datasets. The consensus clustering approach was employed to depict tumor heterogeneity of cancer necroptosis. Subsequently, our study further decoded the heterogeneous clinical outcomes, genomic landscape, biological behaviors, and immune characteristics in necroptosis subtypes. For each patient, providing curative clinical recommendations and developing potential therapeutic drugs were used to promote precise medicine. RESULTS: With the use of the weighted gene coexpression network analysis (WGCNA) algorithm, necroptosis-associated long non-coding RNAs (lncRNAs) (NALRs) were identified in HCC. Based on the NALR expression, two heterogeneous subtypes were decoded with distinct clinical outcomes. Compared to patients in C1, patients in C2 harbored superior pathological stage and presented more unfavorable overall survival and recurrence-free survival. Then, the robustness and reproducibility of necroptosis subtypes were further validated via the nearest template prediction (NTP) approach and classical immune phenotypes. Through comprehensive explorations, C1 was characterized by enriched immune-inflammatory and abundant immune infiltration, while C2 possessed elevated proliferative and metabolic activities and highly genomic instability. Moreover, our results indicated that C1 was more prone to obtain desirable benefits from immunotherapy. For patients in C2, numerous underlying therapeutic agents were developed, which might produce significant efficacy. CONCLUSION: This study identified two necroptosis subtypes with distinct characteristics, decoding the tumor heterogeneity. For an individualized patient, our work tailored corresponding treatment strategies to improve clinical management.
format Online
Article
Text
id pubmed-9363630
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93636302022-08-11 Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma Hu, Bowen Gao, Jie Shi, Jihua Zhang, Feng Shi, Chengcheng Wen, Peihao Wang, Zhihui Guo, Wenzhi Zhang, Shuijun Front Immunol Immunology INTRODUCTION: Necroptosis is a novel pattern of immunogenic cell death and has triggered an emerging wave in antitumor therapy. More evidence has suggested the potential associations between necroptosis and intra-tumoral heterogeneity. Currently, the underlying role of necroptosis remains elusive in hepatocellular carcinoma (HCC) at antitumor immunity and inter-tumoral heterogeneity. METHODS: This study enrolled a total of 728 HCC patients and 139 immunotherapy patients from eight public datasets. The consensus clustering approach was employed to depict tumor heterogeneity of cancer necroptosis. Subsequently, our study further decoded the heterogeneous clinical outcomes, genomic landscape, biological behaviors, and immune characteristics in necroptosis subtypes. For each patient, providing curative clinical recommendations and developing potential therapeutic drugs were used to promote precise medicine. RESULTS: With the use of the weighted gene coexpression network analysis (WGCNA) algorithm, necroptosis-associated long non-coding RNAs (lncRNAs) (NALRs) were identified in HCC. Based on the NALR expression, two heterogeneous subtypes were decoded with distinct clinical outcomes. Compared to patients in C1, patients in C2 harbored superior pathological stage and presented more unfavorable overall survival and recurrence-free survival. Then, the robustness and reproducibility of necroptosis subtypes were further validated via the nearest template prediction (NTP) approach and classical immune phenotypes. Through comprehensive explorations, C1 was characterized by enriched immune-inflammatory and abundant immune infiltration, while C2 possessed elevated proliferative and metabolic activities and highly genomic instability. Moreover, our results indicated that C1 was more prone to obtain desirable benefits from immunotherapy. For patients in C2, numerous underlying therapeutic agents were developed, which might produce significant efficacy. CONCLUSION: This study identified two necroptosis subtypes with distinct characteristics, decoding the tumor heterogeneity. For an individualized patient, our work tailored corresponding treatment strategies to improve clinical management. Frontiers Media S.A. 2022-07-27 /pmc/articles/PMC9363630/ /pubmed/35967375 http://dx.doi.org/10.3389/fimmu.2022.970117 Text en Copyright © 2022 Hu, Gao, Shi, Zhang, Shi, Wen, Wang, Guo and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hu, Bowen
Gao, Jie
Shi, Jihua
Zhang, Feng
Shi, Chengcheng
Wen, Peihao
Wang, Zhihui
Guo, Wenzhi
Zhang, Shuijun
Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
title Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
title_full Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
title_fullStr Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
title_full_unstemmed Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
title_short Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
title_sort necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363630/
https://www.ncbi.nlm.nih.gov/pubmed/35967375
http://dx.doi.org/10.3389/fimmu.2022.970117
work_keys_str_mv AT hubowen necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT gaojie necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT shijihua necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT zhangfeng necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT shichengcheng necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT wenpeihao necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT wangzhihui necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT guowenzhi necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma
AT zhangshuijun necroptosisthrowsnovelinsightsonpatientclassificationandtreatmentstrategiesforhepatocellularcarcinoma